The Potential Paradoxical Neurocognitive Effects of Cannabis Use in Patients with Psychotic Disorders: A Critical Meta-Review of Meta-Analytical Evidence
Restricted accessReview articleFirst published online May, 2023
The Potential Paradoxical Neurocognitive Effects of Cannabis Use in Patients with Psychotic Disorders: A Critical Meta-Review of Meta-Analytical Evidence
The association between cannabis and cognitive functions has been thoroughly studied in psychotic disorders, but conflictual/paradoxical results have emerged. This critical meta-review examined the magnitude of effects of cannabis on neurocognitive functions in patients with psychotic disorders provided by meta-analyses and evaluated the quality of evidence.
Methods:
A systematic search of meta-analyses was performed in PubMed, PsycINFO, Web of Science, and Google Scholar.
Results:
The search retrieved six meta-analyses. Quality of evidence varied from very low to moderate quality. No neurocognitive difference was observed between cannabis users and nonusers in first episode of psychosis samples. Limited evidence showed no significant difference in language, psychomotor functioning, and verbal/visual learning/memory, apart from improvements in verbal and visual memory (recognition). Findings showed better neurocognitive performances in cannabis-using patients for planning/reasoning and working memory. There were tendencies toward significance for processing speed and attention. Most effect sizes showed small to moderate degrees of outperformances in cannabis users. Individuals with lifetime use appeared to show better neurocognitive functions.
Conclusion:
Evidence indicated nonuniform effects of cannabis use across cognitive domains, with some areas suggesting better cognitive performances in cannabis users, entitled the paradoxical effect of the dually diagnosed. Clinical significance of these findings should be interpreted cautiously.
Get full access to this article
View all access options for this article.
References
1.
BarnettJH, WernersU, SecherSM, et al.Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry. 2007; 190:515–520.
2.
KoskinenJ, LöhönenJ, KoponenH, et al.Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull. 2010; 36:1115–1130.
3.
ToftdahlNG, NordentoftM, HjorthøjC. Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study. Soc Psychiatry Psychiatr Epidemiol. 2016; 51:129–140.
4.
NesvågR, KnudsenGP, BakkenIJ, et al.Substance use disorders in schizophrenia, bipolar disorder, and depressive illness: a registry-based study. Soc Psychiatry Psychiatr Epidemiol. 2015; 50:1267–1276.
5.
GreenB, YoungR, KavanaghD. Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry. 2005; 187:306–313.
6.
GreenB, KavanaghD, YoungR. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev. 2003; 22:453–460.
7.
LoweDJ, SasiadekJD, ColesAS, et al.Cannabis and mental illness: a review. Eur Arch Psychiatry Clin Neurosci. 2019; 269:107–120.
8.
HasinDS. US epidemiology of cannabis use and associated problems. Neuropsychopharmacology. 2018; 43:195–212.
9.
VolkowND, BalerRD, ComptonWM, et al.Adverse health effects of marijuana use. N Engl J Med. 2014; 370:2219–2227.
10.
VolkowND, SwansonJM, EvinsAE, et al.Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: A review. JAMA Psychiatry. 2016; 73:292–297.
11.
D'SouzaDC, GaneshS, Cortes-BrionesJ, et al.Characterizing psychosis-relevant phenomena and cognitive function in a unique population with isolated, chronic and very heavy cannabis exposure. Psychol Med. 2020; 50:2452–2459.
12.
Di FortiM, MorganC, DazzanP, et al.High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009; 195:488–491.
13.
MarconiA, Di FortiM, LewisCM, et al.Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016; 42:1262–1269.
14.
Galvez-BuccolliniJA, ProalAC, TomaselliV, et al.Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis. Schizophr Res. 2012; 139:157–160.
15.
VeenND, SeltenJP, van der TweelI, et al.Cannabis use and age at onset of schizophrenia. Am J Psychiatry. 2004; 161:501–506.
16.
Alvarez-JimenezM, PriedeA, HetrickSE, et al.Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012; 139:116–128.
17.
PatelR, WilsonR, JacksonR, et al.Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study. BMJ Open. 2016; 6:e009888.
18.
Manrique-GarciaE, ZammitS, DalmanC, et al.Prognosis of schizophrenia in persons with and without a history of cannabis use. Psychol Med. 2014; 44:2513–2521.
19.
BagotKS, MilinR, KaminerY. Adolescent initiation of cannabis use and early-onset psychosis. Subst Abus. 2015; 36:524–533.
20.
HenquetC, KrabbendamL, SpauwenJ, et al.Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2005; 330:11.
21.
FotiDJ, KotovR, GueyLT, et al.Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry. 2010; 167:987–993.
22.
D'SouzaDC, Abi-SaabWM, MadonickS, et al.Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005; 57:594–608.
23.
Di FortiM, SallisH, AllegriF, et al.Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014; 40:1509–1517.
24.
LargeM, SharmaS, ComptonMT, et al.Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011; 68:555–561.
25.
PatelR, WilsonR, JacksonR, et al.Cannabis use and treatment resistance in first episode psychosis: a natural language processing study. Lancet. 2015; 385:S79.
26.
DellazizzoL, PotvinS, BeaudoinM, et al.Cannabis use and violence in patients with severe mental illnesses: a meta-analytical investigation. Psychiatry Res. 2019; 274:42–48.
27.
ColizziM, TosatoS, RuggeriM. Cannabis and cognition: connecting the dots towards the understanding of the relationship. Brain Sci. 2020; 10:133.
28.
de VosC, LeopoldK, BlankeES, et al.The relationship between cannabis use and cognition in people diagnosed with first-episode psychosis. Psychiatry Res. 2020; 293:113424.
29.
LovellME, AkhurstJ, PadgettC, et al.Cognitive outcomes associated with long-term, regular, recreational cannabis use in adults: a meta-analysis. Exp Clin Psychopharmacol. 2020; 28:471–494.
30.
SchoelerT, KambeitzJ, BehlkeI, et al.The effects of cannabis on memory function in users with and without a psychotic disorder: findings from a combined meta-analysis. Psychol Med. 2016; 46:177–188.
31.
ScottJC, SlomiakST, JonesJD, et al.Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis. JAMA Psychiatry. 2018; 75:585–595.
32.
SmithJL, MattickRP, JamadarSD, et al.Deficits in behavioural inhibition in substance abuse and addiction: a meta-analysis. Drug Alcohol Depend. 2014; 145:1–33.
33.
FigueiredoPR, TolomeoS, SteeleJD, et al.Neurocognitive consequences of chronic cannabis use: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2020; 108:358–369.
34.
KrzyzanowskiDJ, PurdonSE. Duration of abstinence from cannabis is positively associated with verbal learning performance: a systematic review and meta-analysis. Neuropsychology. 2020; 34:359–372.
35.
SchreinerAM, DunnME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol. 2012; 20:420–429.
36.
PlattB, O'DriscollC, CurranVH, et al.The effects of licit and illicit recreational drugs on prospective memory: a meta-analytic review. Psychopharmacology (Berl). 2019; 236:1131–1143.
37.
ZhornitskyS, PelletierJ, AssafR, et al.Acute effects of partial CB(1) receptor agonists on cognition—a meta-analysis of human studies. Prog Neuropsychopharmacol Biol Psychiatry. 2021; 104:110063.
38.
FioravantiM, BianchiV, CintiME. Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. BMC Psychiatry. 2012; 12:64.
39.
BugraH, StuderusE, RappC, et al.Cannabis use and cognitive functions in at-risk mental state and first episode psychosis. Psychopharmacology (Berl). 2013; 230:299–308.
40.
Jockers-ScherüblMC, WolfT, RadzeiN, et al.Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31:1054–1063.
41.
SchnellT, KoetheD, DaumannJ, et al.The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berl). 2009; 205:45–52.
42.
CunhaPJ, RosaPG, Ayres AdeM, et al.Cannabis use, cognition and brain structure in first-episode psychosis. Schizophr Res. 2013; 147:209–215.
43.
LeesonVC, HarrisonI, RonMA, et al.The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophr Bull. 2012; 38:873–880.
44.
Rodríguez-SánchezJM, Ayesa-ArriolaR, MataI, et al.Cannabis use and cognitive functioning in first-episode schizophrenia patients. Schizophr Res. 2010; 124:142–151.
45.
de la SernaE, MayoralM, BaezaI, et al.Cognitive functioning in children and adolescents in their first episode of psychosis: differences between previous cannabis users and nonusers. J Nerv Ment Dis. 2010; 198:159–162.
46.
HannaRC, ShalvoyA, CullumCM, et al.Cognitive function in individuals with psychosis: moderation by adolescent cannabis use. Schizophr Bull. 2016; 42:1496–1503.
47.
González-PintoA, González-OrtegaI, AlberichS, et al.Opposite cannabis-cognition associations in psychotic patients depending on family history. PLoS One. 2016; 11:e0160949.
48.
MeijerJH, DekkerN, KoeterMW, et al.Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. Psychol Med. 2012; 42:705–716.
49.
CoulstonCM, PerdicesM, TennantCC. The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophr Res. 2007; 96:169–184.
50.
MataI, Rodríguez-SánchezJM, Pelayo-TeránJM, et al.Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. Psychol Med. 2008; 38:1257–1266.
51.
CohenJ. Statistical power analysis for the behavioral sciences. New York, NY: Academic Press, 2013.
52.
ElSohlyMA, MehmedicZ, FosterS, et al.Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry. 2016; 79:613–619.
53.
ChandraS, RadwanMM, MajumdarCG, et al.New trends in cannabis potency in USA and Europe during the last decade (2008–2017). Eur Arch Psychiatry Clin Neurosci. 2019; 269:5–15.
54.
BogatySER, LeeRSC, HickieIB, et al.Meta-analysis of neurocognition in young psychosis patients with current cannabis use. J Psychiatr Res. 2018; 99:22–32.
55.
GuyattGH, OxmanAD, VistG, et al.GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol. 2011; 64:407–415.
56.
GuyattGH, OxmanAD, KunzR, et al.GRADE guidelines: 8. Rating the quality of evidence—indirectness. J Clin Epidemiol. 2011; 64:1303–1310.
57.
GuyattGH, OxmanAD, KunzR, et al.GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin Epidemiol. 2011; 64:1294–1302.
58.
GuyattGH, OxmanAD, MontoriV, et al.GRADE guidelines: 5. Rating the quality of evidence—publication bias. J Clin Epidemiol. 2011; 64:1277–1282.
59.
DellazizzoL, PotvinS, LuigiM, et al.Evidence on virtual reality-based therapies for psychiatric disorders: meta-review of meta-analyses. J Med Internet Res. 2020; 22:e20889.
60.
DellazizzoL, PotvinS, GiguèreS, et al. Evidence on the acute and residual neurocognitive effects of cannabis use in adolescents and adults: a systematic meta-review of meta-analyses. Addiction. 2022. DOI:10.1111/add.15764.
61.
MoherD, LiberatiA, TetzlaffJ, et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6:e1000097.
62.
MarderSR, FentonW. Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res. 2004; 72:5–9.
63.
NuechterleinKH, BarchDM, GoldJM, et al.Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004; 72:29–39.
64.
DonoghueK, DoodyGA. Effect of illegal substance use on cognitive function in individuals with a psychotic disorder: a review and meta-analysis. Neuropsychology. 2012; 26:785–801.
65.
Sánchez-GutiérrezT, Fernandez-CastillaB, BarbeitoS, et al.Cannabis use and nonuse in patients with first-episode psychosis: a systematic review and meta-analysis of studies comparing neurocognitive functioning. Eur Psychiatry. 2020; 63:e6.
66.
YücelM, BoraE, LubmanDI, et al.The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull. 2012; 38:316–330.
67.
RabinRA, ZakzanisKK, GeorgeTP. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr Res. 2011; 128:111–116.
68.
PenkWE, FlanneryRBJr., IrvinE, et al.Characteristics of substance-abusing persons with schizophrenia: the paradox of the dually diagnosed. J Addict Dis. 2000; 19:23–30.
69.
MurrayRM, LewisSW. Is schizophrenia a neurodevelopmental disorder?. Br Med J (Clin Res Ed). 1987; 295:681–682.
70.
MurrayRM, PaparelliA, MorrisonPD, et al.What can we learn about schizophrenia from studying the human model, drug-induced psychosis?. Am J Med Genet B Neuropsychiatr Genet. 2013; 162b:661–670.
71.
CaspiA, MoffittTE, CannonM, et al.Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005; 57:1117–1127.
72.
FerraroL, RussoM, O'ConnorJ, et al.Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophr Res. 2013; 150:129–135.
73.
JoyalCC, HalléP, LapierreD, et al.Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr Res. 2003; 63:297–299.
74.
PencerA, AddingtonJ. Substance use and cognition in early psychosis. J Psychiatry Neurosci. 2003; 28:48–54.
75.
PotvinS, JoyalCC, PelletierJ, et al.Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr Res. 2008; 100:242–251.
76.
SalyersMP, MueserKT. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr Res. 2001; 48:109–123.
77.
CareyKB, CareyMP, SimonsJS. Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. J Nerv Ment Dis. 2003; 191:300–308.
78.
PotvinS, BriandC, ProuteauA, et al.CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn. 2005; 59:38–42.
79.
SolowijN, MichiePT. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. J Psychiatry Neurosci. 2007; 32:30–52.
80.
KuntscheE, JordanMD. Adolescent alcohol and cannabis use in relation to peer and school factors: results of multilevel analyses. Drug Alcohol Depend. 2006; 84:167–174.
81.
CreemersHE, DijkstraJK, VolleberghWAM, et al.Predicting life-time and regular cannabis use during adolescence; the roles of temperament and peer substance use: the TRAILS study. Addiction. 2010; 105:699–708.
82.
CaouetteJD, Feldstein EwingSW. Four mechanistic models of peer influence on adolescent cannabis use. Curr Addict Rep. 2017; 4:90–99.
83.
LøbergEM, HugdahlK. Cannabis use and cognition in schizophrenia. Front Hum Neurosci. 2009; 3:53.
84.
CoulstonCM, PerdicesM, TennantCC. The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues. Aust N Z J Psychiatry. 2007; 41:869–884.
85.
CohenM, SolowijN, CarrV. Cannabis, cannabinoids and schizophrenia: integration of the evidence. Aust N Z J Psychiatry. 2008; 42:357–368.
86.
Schnakenberg MartinAM, BonfilsKA, DavisBJ, et al.Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis. Schizophr Res Cogn. 2016; 6:15–21.
87.
RabinRA, BarrMS, GoodmanMS, et al.Effects of extended cannabis abstinence on cognitive outcomes in cannabis dependent patients with schizophrenia vs non-psychiatric controls. Neuropsychopharmacology. 2017; 42:2259–2271.
88.
WrightA, CatherC, GilmanJ, et al.The changing legal landscape of cannabis use and its role in youth-onset psychosis. Child Adolesc Psychiatr Clin N Am. 2020; 29:145–156.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
